Quote this publication Share Print


Opinions on drugs - Posted on Jun 06 2012

Reason for request

Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication “first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations”.


Actual benefit


The actual benefit of TARCEVA in this indication is substantial.

Improvement in actual benefit

IV (mineur)

In the first-line indication of the treatment of NSCLC with EGFR activating mutations, TARCEVA, like IRESSA, provides a minor improvement in actual benefit (level IV) compared to platinum-based chemotherapy.

Contact Us

Évaluation des médicaments

See also